IRulya Therapeutics Inc(IRLA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -125.6 | Insider Own | 6.34% | Shs Outstand | 1.0M | Perf Week | 44.49% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.9M | Perf Month | 29.9% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | -1.39 | Inst Own | 123.64% | Short Float | 6.31% | Perf Quarter | 117.21% |
| Income | -0.09B | P/S | - | EPS this Y | - | Inst Trans | -0.42% | Short Ratio | 2.02 | Perf Half Y | 50.26% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 74.07% | ROA | -76.68% | Short Interest | 0.06M | Perf YTD | -93.99% |
| Book/sh | -34.73 | P/C | 0.35 | EPS past 3/5Y | -2.82% 8.64% | ROE | -153.84% | 52W High | -95.57% ($909.98) | Perf Year | -89.12% |
| Cash/sh | 114.03 | P/FCF | - | Sales past 3/5Y | - | ROIC | -85.24% | 52W Low | 166.69% ($15.10) | Perf 3Y | -79.64% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 43.02% | Gross Margin | - | Volatility(W/M) | 14.18% 11.91% | Perf 5Y | -99.65% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 3.66 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.52 | EPS Q/Q | 82.1% | Profit Margin | - | RSI (14) | 68.35 | Recom | 1.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.52 | Sales Q/Q | - | SMA20 | 30.92% ($30.76) | Beta | 1.8 | Target Price | $74.44 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/14 | SMA50 | 29.43% ($31.11) | Rel Volume | 10.67 | Prev Close | $34.45 |
| Employees | 38 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 56.07% - | SMA200 | -47.04% ($76.04) | Avg Volume(3M) | 0.03M | Price | $40.27 |
| IPO | 2019/5/9 | Option/Short | No/Yes | Trades | 4581 | Volume | 317,325 | Change | 16.89% |
🫁 옛 퀸스 테라퓨틱스가 이름을 바꿔 새로 출범한 미국 임상 단계 바이오테크 기업입니다. 비공개 기업 오르파이 테라퓨틱스와 합병하고 사모 증자를 마친 뒤 사명을 바꿨습니다. 지금은 흡입형 라파마이신 후보물질로 여러 폐 질환을 겨냥한 임상 개발에 집중하고 있습니다.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded more than usual. That is 1067% of its average volume.
IRLA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +74.1% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.7%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 123.6%.
Tap to view numbers
It ranks #435 of 595 in the industry
Based on market cap of $41M.
GRCE#434 Grace Therapeutics Inc $42M PER - IRLA#435 IRulya Therapeutics Inc $41M PER - 
CELU#436 Celularity Inc $41M PER - 
VERU#437 Veru Inc $41M PER - 
TIL#438 Instil Bio Inc $40M PER - 
FAQ
What kind of company is IRLA?
IRLA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IRLA?
The market cap of IRLA is approximately $41M, ranking 4,956 within its sector.
What is the 52-week high and low for IRLA?
IRLA has recorded a 52-week high of $909.98 and a low of $15.10.
